Popular on TelAve
- L2 Aviation Announces Strategic Growth Investment from Argentum - 123
- NEMTAC Announces New Board of Directors Officers for 2024-2025 - 109
- "Monotheism and Devils" is the theologically dedicated sequel of "Prince of Eurasia" of the Islamic cleric and executive producer Prince Oak Oakleyski
- Democracy at Work & The Left Forum Presents Seminar with Professor Richard D. Wolff based on "Understanding Capitalism"
- Sycamore Hills Dentistry Welcomes the Yomi Robot: The Future of Dental Implant Surgery
- GitKraken Launches DevEx Advance Partner Program to Help Atlassian Solution Partners Elevate Their Clients' Developer & DevOps Team Productivity
- Self-eSTEM Celebrates A Decade of Empowering BIPOC Women & Girls in STEM
- Tobu Railway Group's Tobu Kogyo Division Has Renovated the Kotoku Cattle Farm in Nikko National Park and Reopened it as of July 1, 2024
- Energies Media: Unifying Insights Across the Energy Spectrum
- Phinge's Plan to Save Free Speech and Give Everyone the Right to Personal Privacy and Ownership and Monetization of Their Online Data and Content
Similar on TelAve
- New Study Reveals Alarming Cardiac Risks Associated with Electroshock Treatment
- How to Get a Handicap Placard in California: Simplifying the Process for Disabled Drivers HandicapMD.com Offers Easy Online Certification for Disabled
- Dr Joy Dental Clinic Recognized as a Superbrand for 2024
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New Doctor of Behavioral Health Graduates
- Local Provider Roadrunner Health Services Outperforms Corporate Competitors in New Mexico's Correctional Facilities
- Non Profit Organization "The Breast Cancer Fundraiser" Prepares for Breast Cancer Awareness Month
- Addressing Anti-Aging Solutions for America's Faces of ALL Colors
- New Study Warns of High Dose "ADHD" Drugs Inducing Psychosis
- HandicapMD.com Revolutionizes Access to Handicap Placards in New York
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
TelAve News/10842227
IGC Pharma, Inc. (NYSE American: IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database.
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
POTOMAC, Md. - TelAve -- IGC Pharma, Inc. (NYSE American: IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database.
The PREPARE Challenge, is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institute of Health ("NIH"). The competition aims to accelerate the development of more accurate, innovative, and representative tools for Alzheimer's and related dementias. The Disproportionate Impact prize recognizes the submission with the most potential to support algorithms that generalize to populations disproportionately impacted by AD/ADRD.
IGC's entry in Phase 1 of the PREPARE Challenge won 3rd prize overall and the Disproportionate Impact prize. "We are honored to win the two PREPARE prizes. These recognitions underscore IGC's leadership in artificial intelligence ("AI") and deep learning research aimed at improving Alzheimer's disease prediction," commented CEO Ram Mukunda.
There are approximately 400 million individuals in the preclinical stage of Alzheimer's exhibiting early brain changes, such as plaque buildup, that could lead to cognitive decline within 20 years. By harnessing deep learning models, IGC is developing scalable and cost-effective diagnostic predictors that bypass expensive imaging techniques and ultimately predict cognitive decline two decades before symptoms manifest.
More on TelAve News
Early prediction improves patient outcomes and can help significantly reduce caregiving and healthcare costs.
Ram Mukunda continued, "We believe our early prediction AI initiatives can offer significant hope to patients and caregivers, create long time value for shareholders, and alleviate the projected $1 trillion economic burden on the U.S. healthcare system from Alzheimer's disease."
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
More on TelAve News
Forward-looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contacts
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
The PREPARE Challenge, is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institute of Health ("NIH"). The competition aims to accelerate the development of more accurate, innovative, and representative tools for Alzheimer's and related dementias. The Disproportionate Impact prize recognizes the submission with the most potential to support algorithms that generalize to populations disproportionately impacted by AD/ADRD.
IGC's entry in Phase 1 of the PREPARE Challenge won 3rd prize overall and the Disproportionate Impact prize. "We are honored to win the two PREPARE prizes. These recognitions underscore IGC's leadership in artificial intelligence ("AI") and deep learning research aimed at improving Alzheimer's disease prediction," commented CEO Ram Mukunda.
There are approximately 400 million individuals in the preclinical stage of Alzheimer's exhibiting early brain changes, such as plaque buildup, that could lead to cognitive decline within 20 years. By harnessing deep learning models, IGC is developing scalable and cost-effective diagnostic predictors that bypass expensive imaging techniques and ultimately predict cognitive decline two decades before symptoms manifest.
More on TelAve News
- Grand opening of the ResC4EU platform to support companies withstanding supply chain disruptions
- New Study Reveals Alarming Cardiac Risks Associated with Electroshock Treatment
- The Ultimate Guide to Buying Historic Luxury Homes in Winter Park, FL Now Available
- And The Winner Is: Special Request Ft Rey T (AKA) Reynard Thomas
- Allegiant Management Group Launches New Website Following Recent Rebranding
Early prediction improves patient outcomes and can help significantly reduce caregiving and healthcare costs.
Ram Mukunda continued, "We believe our early prediction AI initiatives can offer significant hope to patients and caregivers, create long time value for shareholders, and alleviate the projected $1 trillion economic burden on the U.S. healthcare system from Alzheimer's disease."
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
More on TelAve News
- Celebrating 30 Years: 2024 Diversity Visa Lottery Opens Oct. 2, Offering Life-Changing Opportunities for U.S. Immigration
- Quidax Launches $125,000 Crypto Innovation Pitch, Partners with Moonshot for TC Battlefield
- Wagoner Roofing Launches New Website
- L-Strategies LLC terminates Angie Wong Miami Republican Committeewoman's contract with New Federal State of China NFSC
- Sara Abbas Excites Global Listeners With Much-Anticipated Viral Release Of New Single "Love You From A Distance"
Forward-looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contacts
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
Contact
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
Source: IGC PHARMA
0 Comments
Latest on TelAve News
- Live Good Inc. Receives 2024 "Innovator of the Year" Recognition from Orange County Business Journal in California
- Human Resources Strategy Forum Celebrates 30 Years Empowering Leaders, Shaping the Next Generation of HR Innovators
- Jessica Perrone and HerFinIQ Announce B.I.G. Investors Club: Empowering Women Towards Financial Independence Through Education and Community
- Lightstone Solutions Announces Appointment of Brian Obney as Chief of Staff and Director of Due Diligence
- Royal Photographer Millie Pilkington Launches Wedding Photography Awards with Wedissimo
- AEC Electric Works with The Menke Group to Adopt the Employee Ownership Model with an Employee Stock Ownership Plan (ESOP)
- The Enchanting Tree-Talking Wizards Are Back!
- Pikmykid School Messaging Empowering Schools Across the United States
- Webinar Announcement: Benefits of Using AI in Construction
- Legionnaire Awarded $3.19M AFWERX Contract to Develop Next Generation Air-refueling System
- DeshCap can now contractually guarantee lowest Business Insurance Cost worldwide
- Certified Credit Partners With ScoreNavigator To Provide Cutting-Edge Credit Management Tools
- Vantiva Introduces World's First Commercially Available DOCSIS 4.0 FDD Cable Modem
- Addressing Anti-Aging Solutions for America's Faces of ALL Colors
- New Study Warns of High Dose "ADHD" Drugs Inducing Psychosis
- TLDz Launches Free Class to Get A gTLD for Under $60K!
- Trade Meter AI Joins NVIDIA Inception Program to Advance its AI Stock Analysis Platform
- Kelvin Education Unveils New Website to Transform School Climate and Mental Health Support Across K-12 Districts
- Expert Law Attorneys Seeks Out The Best Law Firms For 2024
- Self-eSTEM Celebrates A Decade of Empowering BIPOC Women & Girls in STEM